<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">219</article-id>
<title-group><article-title>RP-HPLC Method Development and Validation for the Quantitative Determination of Ruxolitinib in Pure Form and Marketed Pharmaceutical Dosage Form</article-title></title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Prathusha</surname><given-names>J</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Ramakrishna</surname><given-names>Utti</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Poojitha</surname><given-names>Kavali</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Amulya</surname><given-names>Kota</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Radhikareddy</surname><given-names>N</given-names></name></contrib>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><month>06</month><year>2024</year></pub-date>
<volume>5</volume>
<issue>2</issue>
<fpage>15</fpage>
<lpage>21</lpage>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/219/rp-hplc-method-development-and-validation-for-the-quantitative-determination-of-ruxolitinib-in-pure"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/219/download"/>
<abstract><p>A novel, simple, accurate, precise, sensitive and specific analytical RP-HPLC method was developed and validated for the quantitative estimation of Ruxolitinib in bulk drugs and pharmaceutical dosage form. Chromatographic separation was achieved on an Symmetry ODS C18 (4.6×250mm, 5µm) analytical column using mobile phase composition of methanol and Phosphate Buffer in ratio of (35: 65 v/v) that was set at a flow rate of 1.0μl/min with detection of 235 nm. The retention time of Ruxolitinib was found to be 3.006min. The drug was analyzed by following the guidelines of International conference on Harmonization (ICH). This drug showing linearity in the concentration range of 6-14µg/ml and the correlation coefficient showing R2 = 0.9996. The % Recoveries showing within the limits. The presentation of the method was validated according to the present ICH guidelines for accuracy, precision and robustness, Linearity, limit of quantification, limit of detection linearity. </p></abstract>
</article-meta>
</front>
</article>